Physician profile
Haley Bauguss
NPI 1093209538
$562.65
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2023: $73.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $73.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $73.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $102.69 | 2021 | |
| Sanofi-Aventis U.S. LLC | $83.21 | 2021 | |
| Pfizer INC. | $66.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $53.45 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.50 | 2021 | |
| Edwards Lifesciences Corporation | $29.33 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $23.25 | 2023 | Ozempic |
| Abbott Laboratories | $21.28 | 2023 | Merlin@Home |
| Eisai INC. | $16.59 | 2021 | |
| Neos Therapeutics, LP | $16.16 | 2021 | |
| Adlon Therapeutics L.P. | $16.07 | 2021 | |
| Amgen INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Bauguss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.